Wall Street analysts are anticipating a rebound for Pfizer stock, with a specific price target being set for the pharmaceutical giant.

An analysis compares the growth trajectories of pharmaceutical giants Pfizer and Gilead, evaluating which company presents a stronger long-term growth story. The comparison focuses on their respective market positions and future potential.

Dividend-paying giants Pfizer, Chevron, and AbbVie are reportedly looking at bold price targets for the year 2027.

The European Union has begun evaluating an experimental vaccine developed by Pfizer for the prevention of Lyme disease in children and adults, aiming to approve the first such vaccine against the tick-borne infection.

Valneva has outlined its 2026 revenue guidance between $145 million and $160 million, while Pfizer aims to make decisions regarding its Lyme disease initiatives within the next 12 months.

Notable insider trading activities have been reported for major companies including Microsoft, Meta, and Pfizer, indicating significant stock transactions by company executives.

Top stock market recommendations for August 6 include Ambuja Cements, Asahi India Glass, and Pfizer. These stocks have been identified as top buy calls by Aakash K Hindocha, Vice President - Research, Nuvama Professional Clients Group/Nuvama Wealth.

Pfizer Inc. published its Q2 2026 earnings call summary, reporting on its financial performance and business updates for the second quarter.

Pfizer has managed to raise its 2026 financial guidance, overcoming a tumble in sales related to its COVID-19 products.

Pharmaceutical giant Pfizer has announced an expansion of its existing multibillion-dollar plan aimed at reducing operational costs across the company.

An analysis comparing Pfizer Inc. and Eli Lilly and Company from an investment perspective, focusing on growth versus value plays in the pharmaceutical sector.

An article analyzes Pfizer's seemingly high dividend yield, explaining why the company's management remains unconcerned about its sustainability.

Over 5 billion PLN owed to the Polish Air Navigation Services Agency is at risk as creditors pursue aviation-related assets, stemming from a dispute between Pfizer and the Polish state.

The Brussels Court of First Instance will hear the appeal filed by the Romanian Air Traffic Services Administration (ROMATSA) against the blocking of funds at Pfizer's request, with the agency reportedly having only a few weeks of funds left.

The Polish Air Navigation Services Agency (PAŻP) is facing a severe financial crisis after Eurocontrol blocked route charge revenues. This action is linked to a court ruling in a dispute between Pfizer and Poland, depriving PAŻP of hundreds of millions of zlotys monthly.

An article explores whether the current bearish sentiment surrounding pharmaceutical giants Pfizer and Gilead Sciences presents a potential contrarian investment opportunity.

Pfizer is reportedly on track to launch a new weight-loss medication, aiming to achieve a similar market impact as its successful cholesterol drug, Lipitor.

The European Organisation for the Safety of Air Navigation has frozen funds intended for the Polish Air Navigation Services Agency due to a lawsuit filed by Pfizer against Poland over unpaid COVID-19 vaccines.

Pfizer has seized the account of the Polish Air Navigation Services Agency (PAŻP) through EUROCONTROL, reportedly over a dispute concerning 5.6 to 6.5 billion PLN related to uncollected COVID-19 vaccine doses. This action highlights a financial conflict stemming from vaccine procurement.

Emergency evacuations occurred at the former Pfizer building in Manhattan following concerns about its structural integrity, prompting a review by the NYC Department of Buildings.

Yahoo reports on Monday's top Wall Street analyst research calls, covering various companies including Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, and T-Mobile.

The accounts of Romania's air traffic control service have been blocked due to unpaid COVID-19 vaccines. Pharmaceutical giant Pfizer sued Romania for unpurchased vaccines under a contract with the European Commission, leading to the seizure of ROMATSA's accounts.

Christina Michaelidou has been appointed as the new Medical Director of Pfizer Hellas, marking a new chapter in the scientific leadership of the company. Her appointment is expected to bring fresh perspectives to the pharmaceutical firm.

Romania's air navigation agency, ROMATSA, is reportedly facing enforcement measures due to a lawsuit involving Pfizer.

An analysis compares Pfizer and Verizon Communications to determine which high-yielding dividend stock presents a better investment opportunity.

A Pfizer Inc. executive has claimed that China is now surpassing Europe in the fields of drug innovation and development. This assessment highlights a shift in the global pharmaceutical landscape.

An analysis compares AbbVie and Pfizer to determine which pharmaceutical giant's stock presents a better investment opportunity for 2026.

Nike has announced the appointment of David Denton, formerly Pfizer's CFO, as its new finance chief. This change in leadership comes as Wendy's also picks Steve Cirulis as its finance and strategy chief.

Nike has announced that David Denton, currently the CFO of Pfizer, will replace Matthew Friend as the company's new Chief Financial Officer.

Pfizer Inc. (PFE) CEO Albert Bourla provides his take on the company's current standing and future outlook.

A clinical trial for Pfizer's lung cancer drug has failed to demonstrate an improvement in patient survival. This outcome marks a setback for the pharmaceutical company's efforts in lung cancer treatment.

An article analyzes the potential annual dividend income for an investor holding 500 shares each of pharmaceutical giants Pfizer and Johnson & Johnson.

Pfizer's stock experienced a decline as the company's CFO transition raised concerns and tested confidence in its 2026 financial outlook.

Rigel Pharmaceuticals is set to launch Veppanu in August, while Arvinas and Pfizer have secured a $70 million upfront payment for a cleared deal.

A report highlights recent insider trading activities involving prominent companies such as Microsoft, Tesla, and Pfizer, among other notable names.

ORIC Pharmaceuticals saw its stock gain after Stifel resumed its coverage with a 'Buy' rating, anticipating an upcoming readout from Pfizer.

Poland has received a demand from Belgium for nearly 170 million PLN (approximately €37 million) in registration tax related to an ongoing court case between Poland and Pfizer BioNTech concerning unused and unpaid vaccine doses.

Despite Pfizer stock offering a 6.7% dividend yield, an under-the-radar reason suggests holding off on purchasing shares at the current $25 price.

Romania has received an official notification to pay over 3.4 billion lei to Pfizer after losing a COVID-19 vaccine lawsuit in the first instance, with ministers Cseke and Nazare explaining potential solutions.

Pfizer and Zai Lab have received approval from Chinese authorities for Tivdak, their cervical cancer therapy, expanding its market reach.

Analysts are examining whether Pfizer's dividend can withstand an upcoming patent cliff, with a $10.5 billion cancer investment potentially holding the key to its survival.

Pfizer has announced a partnership with Chai Discovery to utilize its AI platform in drug development, joining other pharmaceutical giants like Eli Lilly in investing in AI drug discovery startups. This collaboration aims to accelerate the process of bringing new medicines to market.

Pfizer Inc. (PFE) is reportedly expanding its cancer pipeline through a landmark partnership with Innovent. This collaboration aims to strengthen Pfizer's presence in oncology research and development.

This week's notable healthcare headlines highlight developments concerning UnitedHealthcare, Pfizer, and Eli Lilly.

Analysts have released conflicting sentiments on several consumer cyclical companies, including Citi Trends, Caesars Entertainment, and Yeti Holdings. Additionally, insights were provided for healthcare companies like Phreesia, Agilent, and Pfizer, and other consumer cyclical firms such as Tesla and BMW.

Bank of America has increased its price target for Pfizer after the pharmaceutical giant reported strong first-quarter earnings.

Pfizer's CEO is reportedly utilizing artificial intelligence to inform his most significant business decisions, a trend echoed by 64% of CEOs who are quietly shifting their portfolios based on AI insights.

Pfizer has won a trademark dispute against Merck in Singapore concerning a vaccine brand, securing its intellectual property rights.

Aristotle University and Pfizer have signed a Memorandum of Understanding to strengthen innovation, entrepreneurship, and connection with the labor market. The signing took place during the Aristotle Innovation Forum.

Financial commentator Jim Cramer has provided a range of stock recommendations, advising on whether to buy, hold, or avoid various companies including TJX, Caterpillar, Eli Lilly, and Cloudflare. He also expressed regret over selling Cisco and cautioned against buying certain stocks at their current highs.

A new prediction suggests that pharmaceutical giant Pfizer is poised to beat the broader market over the coming five-year period.

Pfizer's net income experienced a decline in the first quarter, prompting questions about the safety and sustainability of its dividend.

Moderna's stock saw a 6% increase today, prompting questions about its performance relative to other major vaccine manufacturers like Pfizer and Novavax. The surge indicates investor interest in the company's market position.

Pfizer's first-quarter results indicate that its newer pharmaceutical products are significantly contributing to the company's overall financial performance.

Pfizer announced its first-quarter results, surpassing analyst estimates for both earnings and revenue, while also reaffirming its financial projections for 2026.

România aşteaptă răspuns de la compania Pfizer, după ce i-a transmis că doreşte convertirea sumei de 3,4 miliarde de lei, la care se adaugă penalităţi, datorată pentru achiziţia de vaccin Covid-19,…

Ahead of its Q1 earnings, analysts are expressing optimism about Pfizer's strong drug pipeline, with particular focus on its obesity pipeline and upcoming guidance.

Guggenheim analysts have reiterated their 'Buy' rating for Pfizer, anticipating positive catalysts from the pharmaceutical giant's upcoming pipeline developments.

Financial analysts are presenting varied perspectives on Pfizer (PFE) stock, with some expressing bullish sentiment and recommending it as a strong investment. Others, like Morgan Stanley, maintain an "Equal Weight" rating due to patent concerns, while still considering it among the best medical stocks.

Goldman Sachs has revised its stock forecast for pharmaceutical giant Pfizer, reflecting new market analysis.

BridgeBio Pharmaceuticals saw gains after reaching a settlement in its patent dispute with Pfizer regarding the drug Vyndamax.

Pfizer (PFE) is being evaluated as one of the best Fortune 500 dividend stocks for investment, suggesting its strong position for dividend-seeking investors.

An analysis evaluates how well pharmaceutical giants Pfizer and Johnson & Johnson are prepared to navigate the challenges posed by upcoming patent expirations.

An article offers a prediction on where Pfizer's stock will be positioned by the year 2030.

A fact-checking article refutes claims that a leaked video proves Pfizer concealed information about COVID-19 vaccines, explaining that the video uses out-of-context statements from a biochemist.

Recent notable stock trades have included major companies such as Netflix, Coca-Cola, and Pfizer, drawing attention in the market.

An analysis compares Pfizer Inc. (PFE) and BioNTech SE (BNTX) to determine which pharmaceutical giant is better positioned for the market and healthcare landscape in the post-COVID era.

Pfizer is grappling with significant challenges, including sliding vaccine revenues and concerns that it overpaid for new drugs, putting pressure on its leadership.

The Polish State Treasury has filed an appeal against a Brussels court's decision in a dispute with Pfizer concerning 5.6 billion PLN for undelivered COVID-19 vaccines.

A range of stocks including SpaceX, Palantir, AMD, Marvell, Caterpillar, and Pfizer are highlighted as key indicators explaining current market trends.

Pfizer has raised its revenue outlook for the year after reporting quarterly earnings that surpassed analyst estimates.

The Romanian air traffic operator ROMATSA is scheduled for a January 2027 court hearing in a case concerning a Pfizer revenue freeze.

An analysis addresses whether Pfizer's 7% dividend yield is sustainable or too good to be true, providing a straightforward answer for investors.

The Romanian Ministry of Finance has filed an appeal against a Brussels court decision that blocked payments owed to ROMATSA by Eurocontrol, following a forced execution request by Pfizer against the Romanian state.

Pfizer is highlighted as a potential candidate for investors seeking cheap income stocks, suggesting it could be a valuable addition to a portfolio.

Pfizer and BioNTech are facing global patent lawsuits from Arbutus and Roivant Sciences concerning the technology used in their COVID-19 vaccines.

An analysis suggests that Pfizer's integration of Seagen is likely to lead to long-term outperformance in the oncology market compared to Amgen, according to financial observers.

Romatsa, the Romanian air traffic control agency, has warned of limited financial resources after its accounts were seized in a lawsuit with Pfizer. Polish air traffic control also reported account seizures in the same legal dispute, prompting appeals to authorities for intervention.

A dispute between Poland and Pfizer has led to Eurocontrol seizing route charges from PAŻP (Polish Air Navigation Services Agency), prompting the government to seek additional funds and PAŻP to prepare a formal objection.

Polska Agencja Żeglugi Powietrznej poinformowała w czwartek, że jej środki z tytułu opłat trasowych zostały zablokowane w wyniku wyroku belgijskiego sądu w sprawie sporu między Pfizerem a…

A former Pfizer building in New York City is at risk of collapse following a dangerous incident. Authorities have stabilized the structure, which had partially abated.

Pfizer's dividend record is analyzed to show how its tax treatment can be separate from the company's underlying business momentum.

A heated exchange has erupted between Romanian officials Vlad Voiculescu and Alexandru Rogobete regarding the Pfizer dossier. The dispute involves accusations of 'treason' and 'public manipulation' between the two.

Pfizer Inc. (PFE) is highlighted as a top dividend stock by hedge funds, coinciding with a significant FDA milestone for its drug Ibrance.

Pfizer's CEO highlighted the company's strong balance sheet for potential deals, with an article suggesting a 'perfect next acquisition target' for the pharmaceutical giant.

Romania's Minister of Finance explained how funds collected by EUROCONTROL for ROMATSA were garnished as part of a legal dispute between the Romanian state and Pfizer, with the government now exploring all legal and budgetary options.

The legal dispute between Romania and Pfizer has escalated, resulting in a seizure of over 3.4 billion lei from ROMATSA. The funds collected by EUROCONTROL were targeted in this action.

An analysis suggests that Pfizer could be an underrated stock, particularly in the context of its GLP-1 drug development.

Pfizer's stock is under scrutiny after a CFO departure and a clinical trial miss, raising questions about the company's future valuation. Investors are evaluating whether to maintain their positions in the pharmaceutical giant.

Pfizer (PFE) has reaffirmed its fiscal year 2026 outlook despite recent leadership changes. The company maintains its financial projections for the coming years.

Nike has appointed Pfizer's Chief Financial Officer, offering a substantial $7.3 million 'new hire' cash award as part of the compensation package.

Nike has announced the hiring of Pfizer's Denton to take over as its Chief Financial Officer, replacing the departing CFO.

An appeals court has upheld Pfizer's patent victory against Enanta Pharmaceuticals regarding its COVID-19 pill.

Eli Lilly currently holds a dominant position in the obesity drug market, while Pfizer has made strategic investments to compete in the sector in the near future.

Pfizer announced that its Chief Financial Officer, Dave Denton, will step down from his position effective August 15.

Moderna's stock has seen a 94% increase this year, prompting questions about its performance compared to other vaccine companies like Pfizer and Novavax.

Notable analyst calls this week highlight Pfizer, AMD, and Intel among their top stock picks.

Poland is facing additional costs of nearly 170 million PLN from Belgium, on top of a first-instance ruling to pay almost 6 billion PLN, in a lawsuit filed by Pfizer over uncollected COVID-19 vaccines from 2022.

Pharmaceutical giant Pfizer is seeking 650 million euros from Romania for COVID-19 vaccine doses that the country had ordered but ultimately did not collect.

Pfizer's stock saw a notable increase in value today, attracting investor attention.

Romania's Finance Minister Alexandru Nazare stated that the 680 million euros owed to Pfizer represents the largest damage to the state budget, as discussions with the company continue.

Pfizer has released new data on its experimental weight-loss shot and outlined a strategy to become a leader in the competitive weight-loss drug market, aiming to power its growth in the coming decade.

An investment analysis compares Pfizer and Merck, examining their potential for high yield versus higher overall returns for investors.

An investment comparison evaluates whether AbbVie or Pfizer represents a better buying opportunity in the healthcare stock sector for the year 2026.

An analysis examines how Pfizer's stock performance compares to that of other companies within the healthcare sector.

BridgeBio has received a downgrade from Raymond James, attributed to the loss of exclusivity for Pfizer's drug Vyndamax.

A Wall Street analyst has projected a potential 38% increase in Pfizer (PFE) stock, suggesting a strong outlook for the pharmaceutical company.

Reports circulating online suggesting that Pfizer, known for its COVID-19 vaccine, is also developing a vaccine against hantavirus have been identified as false.

Wolfe Research reports that ongoing uncertainty surrounding COVID-19 continues to negatively impact the financial outlook for pharmaceutical giant Pfizer (PFE).

Pfizer has outlined its strategy to ensure growth over the next five years, detailing the initiatives and plans expected to drive its future performance.

Pfizer and Arvinas have announced a licensing deal with Rigel Pharmaceuticals for a new breast cancer therapy.

An article explores whether recent developments indicate that pharmaceutical giant Pfizer's aggressive growth strategy is beginning to yield positive results.

The article compares Pfizer and Eli Lilly's distinct strategies and investment approaches regarding mergers and acquisitions within the pharmaceutical industry.

Pfizer (PFE) is highlighted as one of the best high-volume stocks for investment, according to recent analysis.

Pfizer's management has reportedly addressed and silenced skeptics regarding the company's 6.5% dividend yield, which some initially viewed as too good to be true. This suggests a reaffirmation of the dividend's sustainability.

Pfizer is grappling with a significant $17 billion revenue void, raising questions about the future performance of its stock.

Pharmaceutical giant Pfizer is banking on its new obesity and cancer drugs to drive a return to growth for the company after 2028.

Pfizer reported its first-quarter 2026 earnings, which surpassed analyst estimates. The pharmaceutical giant attributed the strong performance to the growth of its newer drug portfolio.

An investment strategy outlines how to potentially earn $500 a month from Pfizer stock. This advice comes ahead of the company's upcoming first-quarter earnings report.

An analysis examines the performance of pharmaceutical giants Pfizer and Moderna, determining which company has emerged as a winner in the post-Covid era.

A report authored by Dr. Joseph Fraiman via the Brownstone Institute claims that the media is not addressing serious adverse event signals found in Pfizer and Moderna mRNA Covid-19 vaccine trials.

Pfizer has announced a successful outcome in a late-stage clinical trial for its multiple myeloma therapy, Elrexfio. This marks a significant development in the treatment options for the blood cancer.

The article examines whether Wall Street analysts hold a bullish sentiment towards Pfizer stock, providing insights into their current recommendations and market expectations for the pharmaceutical giant.

BridgeBio's stock saw gains following reports of a settlement in a patent dispute involving Pfizer's drug Vyndamax.

Pfizer's turnaround efforts are reportedly gaining traction, but the company faces the challenge of new products needing to offset the impact of its upcoming patent cliff.

The future performance of Pfizer stock is being analyzed as a race between the success of its new drug pipeline and the expiration of its older patents.

An analysis compares the performance of leading drugmaker stocks, including Merck, Pfizer, and Amgen, to determine which has dominated in 2026.

A significant step has been taken in the fight against Lyme disease as the European Medicines Agency (EMA) begins evaluating the application for a vaccine candidate developed by Pfizer and Valneva, which could become the first human vaccine against the disease in Europe if approved.

A summary of notable healthcare news for the week highlights developments concerning major pharmaceutical companies Eli Lilly, Novo Nordisk, and Pfizer.

An analysis compares Pfizer and Merck as dividend investment options following their respective second-quarter earnings reports, evaluating which company presents a smarter dividend play.

United Parks & Resorts, Pfizer, MasterBrand, and Ibstock each held their Q2 earnings calls, providing key financial updates and insights into their performance for the quarter. These calls highlighted the latest financial results and future outlooks for the respective companies.

Several companies, including NuScale Power, Cadre Holdings, and NiSource, have released their Q2 2026 earnings previews. Superior Group of Companies, Inc. also provided a summary of its Q2 2026 earnings call.

Analysts are setting expectations for Pfizer's second-quarter earnings, with investors keenly awaiting the pharmaceutical giant's financial report.

The Polish Air Navigation Services Agency (PAŻP) is actively working to unblock its funds, which have been seized as part of a multi-billion-dollar dispute with Pfizer, with a Brussels court set to hear PAŻP's objection.

Romania has appealed a decision by the Brussels Court that resulted in the blocking of funds for ROMATSA, the national air traffic services administration, stemming from a dispute involving Pfizer.

Pfizer received a platinum award at the 'Diversity & Inclusion Awards 2026' for its groundbreaking DEI strategy, which is recognized for transforming the pharmaceutical sector.

Pfizer has paid out $14.6 billion in dividends over the past 18 months, raising questions about its ability to maintain this through an upcoming patent cliff.

Pfizer (PFE) has announced that the FDA has approved PADCEV in combination with Keytruda for the treatment of MIBC (muscle-invasive bladder cancer).

The funds of Poland's air-traffic agency have been frozen as Pfizer enforces a €1.3 billion ruling for the country's unpaid Covid-19 vaccines. The prime minister stated the government would ensure the agency receives funds to maintain operations and air-traffic safety.

Pfizer has received FDA label expansion for its drug Padcev when used in combination with Merck’s Keytruda for the treatment of bladder cancer.

Polish Prime Minister Donald Tusk expressed outrage over the previous Morawiecki government's handling of Pfizer vaccine orders, stating they failed to collect or pay for vaccines, which led to funds being blocked for the Polish Air Navigation Services Agency.

Jim Cramer has offered diverse insights on the stock market, including his reluctance to recommend Pfizer despite its dividend, defending a struggling tech giant, and highlighting future earnings projections for Oracle and Meta's entry into the neocloud business.

Pfizer, Alnylam, and BridgeBio shares saw gains following a late-stage trial setback for AstraZeneca and Ionis.

An opinion piece suggests that Pfizer's dividend may carry more risk than investors commonly believe, prompting a closer look at its sustainability.

The Romanian Ministry of Finance has launched the seventh edition of its FIDELIS program this year, allowing resident and non-resident individuals over 18 to invest in government bonds denominated in Lei and Euro.

Former Romanian Health Minister Alexandru Rogobete commented on the Pfizer enforcement action against Romatsa, suggesting that the complex situation is being politicized and that Romania should continue negotiations regarding the Pfizer contract.

Romatsa's accounts have been garnished at the request of Pfizer, prompting Romania to announce that it will contest these measures in a Belgian court.

Interim Prime Minister Ilie Bolojan announced that Romatsa, with government lawyers, will file a challenge in Belgium next week against Pfizer's enforcement procedure targeting the Romanian state for 600 million euros.

An analysis evaluates whether Pfizer Inc. (PFE) is currently a good stock to buy, providing insights into its investment potential.

Pfizer is being highlighted as a strong dividend stock for income investors, with analysts suggesting it's a good buy for long-term holdings. The company's dividend yield is noted as attractive compared to the average.

Pfizer has been granted an FDA label expansion for its breast cancer drug, Ibrance.

Pharmaceutical giant Pfizer has been dismissed from a multi-state lawsuit in the US alleging drug price-fixing.

Nike has named David Denton, formerly an executive at Pfizer, to replace Matthew Friend as its new Chief Financial Officer.

Knauer GmbH, a Berlin-based lab equipment manufacturer, has become a 'hidden champion' after receiving an order from Pfizer during the COVID-19 pandemic, earning accolades from Angela Merkel.

Pfizer has indicated it does not anticipate making any significant acquisitions in the next couple of years, instead planning to pursue a different strategic approach.

Pfizer's dividend yield is reportedly ten times larger than Eli Lilly's, leading to questions about which stock offers a better return for income-focused investors.

Pfizer's Chief Financial Officer has announced their departure from the pharmaceutical giant to transition into the consumer goods sector.

Pfizer's CEO has outlined when the company might return to generating high-single-digit growth, providing an outlook on its future financial performance.

An investment analysis suggests Pfizer (PFE) is a leading longevity stock to consider buying now, highlighting its potential in the growing market for health and aging-related investments.

Romania is attempting to reach a settlement with Pfizer regarding vaccine debt, which is currently incurring monthly penalties of EUR 2.5 million.

A recent $25 billion acquisition by Pfizer is seen as unlocking a new era of growth for the company, making it a flawless safe-haven investment for retirees.

An analysis compares Lexicon Pharmaceuticals and Pfizer to determine which drugmaker stock presents a better investment opportunity for 2026.

Wall Street analysts have released their top stock picks for Wednesday, including recommendations for companies such as Nvidia, Tesla, Cava, Netflix, Chipotle, Pfizer, and Nike. These calls provide insights into potential investment opportunities.

Analysts predict that several Chinese biotechnology companies are on track to introduce their own branded medications to consumers in Europe and the US within the next 10 to 15 years. This development signals a significant shift in the global pharmaceutical landscape.

Pfizer announced that mid-stage trial data supports monthly dosing for its GLP-1 therapy, indicating potential for a new treatment option.

An analysis compares Bristol Myers and Pfizer to determine which of the two pharmaceutical companies offers a better high-yield dividend stock investment.

An analysis explores whether Pfizer stock represents a 'value trap' for investors or a generational investment opportunity.

Pfizer has entered into a deal worth up to $10.5 billion with China's Innovent Biologics to develop next-generation cancer therapies, marking a significant collaboration in the pharmaceutical sector.

A report suggests that insiders not buying Pfizer stock at $26 could be a positive indicator for the company's future performance.

Analysts are evaluating BP and Cheniere Energy (LNG) as potential top LNG stocks to buy in 2026, while also considering Pfizer Inc. (PFE) among the best medical stocks for investment according to billionaires. These assessments provide insights into future investment opportunities in the energy and pharmaceutical sectors.

An analysis compares AbbVie and Pfizer to determine which company offers a better investment opportunity as a dividend stock today.

Aristotle University and Pfizer Hellas have signed a memorandum of cooperation aimed at linking the academic community with entrepreneurship and innovation.

Rigel Pharmaceuticals has finalized an agreement with Arvinas and Pfizer concerning a new drug for breast cancer treatment.

Pfizer has been granted a label expansion in Europe for its hemophilia therapy, Hympavzi, broadening its approved uses.

An article provides a financial analysis of Pfizer, discussing whether its stock is a recommended buy, sell, or hold position for investors looking towards 2026.

Amid public concern over hantavirus, misinformation spreaders on social media are falsely claiming that the virus is a side effect of Pfizer's COVID-19 vaccines.

This week's notable healthcare headlines highlight developments concerning major industry players such as UnitedHealth, Pfizer, and CVS Health.

Pfizer is experiencing sales growth primarily propelled by its cancer treatments, while revenue from Covid-related products continues to dwindle.

Pfizer has surpassed its first-quarter expectations, driven by strong growth from its newer product lines.

Jim Cramer indicated that he would prefer to invest in bonds for a good yield rather than Pfizer stock, suggesting a less favorable view on Pfizer's dividend prospects.

An analysis suggests that Pfizer's stock is currently priced as if it has little growth potential, indicating a pessimistic outlook on its future performance.

Pfizer recently secured a notable achievement, likely a regulatory approval or business success, which has garnered significant attention from Wall Street.

An article provides financial analysis and recommendations on whether to buy, sell, or hold Pfizer stock, currently priced at $27.

Pfizer has secured deals to extend the patent life for one of its top-selling rare disease drugs, ensuring continued market exclusivity.